Where to buy tremelimumab/tremelimumab

Tremelimumab/Tremelimumab is a fully humanized anti-cytotoxic T lymphocyte-associated protein 4 (CTLA-4) IgG2 monoclonal antibody. CTLA-4, also known as CD152, is a transmembrane receptor constitutively expressed on regulatory T cells and promotes immunosuppression in the tumor microenvironment. It is an inhibitory molecule capable of regulating T cell expansion and differentiation; in particular, its inhibitory activity is related to the binding of B7-1/B7-2 ligands.

Tremelimumab is also a negative regulator of immune responses and a target for cancer therapy. Blocking CTLA-4 with tremelimumab allows T cells to proliferate and attack tumor cells. Tremelimumab has been tested on different cancer types, including mesothelioma, bladder, lung, melanoma, liver, and head and neck cancer, but despite some promising results, it is currently approved by the U.S. Food and Drug Administration (FDA) for the treatment of non-small cell lung cancer as well as unresectable hepatocellular carcinoma (HCC).

Tremelimumab/Tematumumab is a new type of cancer immunotherapy drug. It has not yet been launched in the country, so it cannot be included in the medical insurance. Domestic patients cannot yet purchase this drug and can only buy it through overseas channels. It is understood that the US version of temsitumumab original drug sold overseas may cost more than more than 3,000 US dollars per box, and the specification is 300mg/50mL (20mg/mL). The price is still relatively expensive. At present, we are not aware of the production and release of generic drugs of temsitumumab. For specific overseas prices and drug details, please consult Yaode Medical Consultants.